Exhibit 99.6

FINANCIAL STATEMENTS OF

SYBRON DENTAL SPECIALTIES, INC.

AS OF MARCH 31, 2006 AND SEPTEMBER 30, 2005

AND

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2005 AND 2006

PART I - FINANCIAL INFORMATION

ITEM 1. Financial Statements

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	March 31, 2006		September 30, 2005
	(in thousands, except per share amounts)
ASSETS
Current assets:
Cash and cash equivalents	$	75,796	$	58,572
Accounts receivable (less allowance for doubtful receivables of $3,154 and $3,007 at March 31, 2006 and September 30, 2005, respectively)		116,820		112,500
Inventories		96,361		92,840
Deferred income taxes		4,167		7,788
Prepaid expenses and other current assets		22,547		12,261
Total current assets		315,691		283,961
Property, plant and equipment, net of accumulated depreciation of $ 125,858 and $117,252 at March 31, 2006 and September 30, 2005, respectively		86,545		87,762
Goodwill		290,069		295,306
Intangible assets, net		63,694		50,882
Other assets		29,893		32,507
Total assets	$	785,892	$	750,418
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	19,497	$	20,135
Current portion of long-term debt		143		733
Income taxes payable		15,221		11,822
Accrued payroll and employee benefits		29,747		31,537
Accrued rebates		6,298		9,336
Accrued interest		3,661		3,519
Other current liabilities		18,977		15,412
Total current liabilities		93,544		92,494
Long-term debt		52,952		61,099
Senior subordinated notes		150,000		150,000
Deferred income taxes		22,423		16,405
Other non-current liabilities		20,808		28,267
Total liabilities		339,727		348,265
Stockholders’ equity:
Preferred stock, $0.01 par value; authorized 20,000 shares, no shares outstanding		—		—
Common stock, $0.01 par value; authorized 250,000 shares, 40,553 and 40,395 shares issued and outstanding at March 31, 2006 and September 30, 2005, respectively		406		404
Additional paid-in capital		128,730		118,448
Retained earnings		298,055		264,841
Accumulated other comprehensive income		18,974		18,460
Total stockholders’ equity		446,165		402,153
Total liabilities and stockholders’ equity	$	785,892	$	750,418

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

1

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

	Three Months Ended March 31,						Six Months Ended March 31,
	2006			2005			2006			2005
	(in thousands, except for per share amounts)						(in thousands, except for per share amounts)
Net sales	$	182,786		$	165,056		$	340,817		$	314,096
Cost of sales
Cost of products sold		78,141			71,787			146,172			135,460
Restructuring charges		—			84			10			84
Total cost of sales		78,141			71,871			146,182			135,544
Gross profit		104,645			93,185			194,635			178,552
Selling, general and administrative expenses		68,866			59,207			130,120			116,695
Restructuring charges		1			488			17			488
Amortization of intangibles		1,299			559			4,113			1,056
Total selling, general and administrative expenses		70,166			60,254			134,250			118,239
Operating income		34,479			32,931			60,385			60,313
Other income (expense):
Interest expense, net		(4,106	)		(4,420	)		(7,963	)		(9,237	)
Amortization of deferred financing fees		(2,346	)		(416	)		(2,759	)		(831	)
Other, net		226			490			273			456
Income before income taxes		28,253			28,585			49,936			50,701
Income taxes		9,567			9,147			16,722			16,224
Net income	$	18,686		$	19,438		$	33,214		$	34,477
Basic earnings per share	$	0.46		$	0.49		$	0.82		$	0.87
Diluted earnings per share	$	0.44		$	0.47		$	0.79		$	0.84
Weighted average shares outstanding:
Basic		40,518			39,986			40,463			39,732
Diluted		42,029			41,485			42,029			41,276

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

2

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY AND COMPREHENSIVE

INCOME

FOR THE SIX MONTHS ENDED MARCH 31, 2006

(UNAUDITED)

	Common Stock			Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income			Total Stockholders’ Equity			Total Comprehensive Income
	Number of Shares	Par Value
	(in thousands)
Balance at September 30, 2005	40,395	$	404	$	118,448	$	264,841	$	18,460		$	402,153
Comprehensive income:
Net income	—		—		—		33,214		—			33,214		$	33,214
Translation adjustment	—		—		—		—		(637	)		(637	)		(637	)
Unrealized gain on derivative instruments	—		—		—		—		1,151			1,151			1,151
Total comprehensive income	—		—		—		33,214		514			33,728		$	33,728
Issuance of common stock from stock options exercised	122		2		1,982		—		—			1,984
Stock compensation expense	—		—		6,264		—		—			6,264
Income tax benefit from issuance of stock under employee stock plan and stock options exercised	—		—		887		—		—			887
Issuance of common stock from Employee Stock Purchase Plan	36		—		1,149		—		—			1,149
Balance at March 31, 2006	40,553	$	406	$	128,730	$	298,055	$	18,974		$	446,165

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

3

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six Months Ended March 31,
	2006			2005
	(in thousands)
Cash flows from operating activities:
Net income	$	33,214		$	34,477
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		9,446			7,264
Amortization of intangible assets		4,113			1,056
Amortization of deferred financing fees		2,759			831
Loss on sales of property, plant and equipment		13			84
Provision for losses on doubtful receivables		415			431
Inventory provisions		2,097			3,203
Deferred income taxes		(662	)		(557	)
Income tax benefit from issuance of stock under employee stock plan and stock options exercised		887			4,736
Changes in assets and liabilities, net of effects of businesses acquired:
Increase in accounts receivable		(4,467	)		(1,554	)
Increase in inventories		(5,082	)		(5,843	)
Increase in prepaid expenses and other current assets		(2,379	)		(429	)
Decrease in accounts payable		(638	)		(3,766	)
Increase/(decrease) in income taxes payable		2,897			(2,519	)
Increase/(decrease) in accrued payroll and employee benefits		(1,790	)		54
Decrease in accrued rebates		(3,038	)		(2,840	)
Increase in accrued interest		142			164
Increase in other current liabilities		3,565			914
Net change in other assets and liabilities		8,101			721
Net cash provided by operating activities		49,593			36,427
Cash flows from investing activities:
Capital expenditures		(8,329	)		(6,342	)
Proceeds from sales of property, plant and equipment		7			938
Net payments for businesses acquired		—			(46,049	)
Acquisition escrow deposit		(7,907	)		—
Payments for intangibles		(386	)		(849	)
Net cash used in investing activities		(16,615	)		(52,302	)
Cash flows from financing activities:
Proceeds from credit facility		137,100			86,000
Principal payments on credit facility		(145,710	)		(75,607	)
Settlement of derivative instruments		(8,384	)		—
Principal payments on long-term debt		(127	)		(292	)
Payment of deferred financing fees		(1,164	)		—
Proceeds from exercise of stock options		1,984			10,254
Proceeds from employee stock purchase plan		1,149			771
Net cash provided by/(used in) financing activities		(15,152	)		21,126
Effect of exchange rate changes on cash and cash equivalents		(602	)		1,774
Net increase in cash and cash equivalents		17,224			7,025
Cash and cash equivalents at beginning of period		58,572			40,602
Cash and cash equivalents at end of period	$	75,796		$	47,627
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	$	8,732		$	9,592
Cash paid during the period for income taxes	$	12,240		$	13,567

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

4

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN THOUSANDS EXCEPT PER SHARE AMOUNTS)

1. OVERVIEW AND BASIS OF PRESENTATION

We are a leading manufacturer of both a broad range of value-added products for the dental profession, including the specialty markets of orthodontics, endodontics and implantology, and a variety of infection prevention products for use by the dental and medical professions. Our fiscal year ends on September 30. The quarters ended March 31, 2006 and 2005 are the second quarters of our fiscal years 2006 and 2005, respectively.

When we use the terms “SDS,” “we,” “us,” “Company,” or “our” in our consolidated financial statements, unless the context requires otherwise, we are referring to Sybron Dental Specialties, Inc. and its subsidiaries.

We have prepared the condensed consolidated financial statements presented herein following the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted. In the opinion of management, all adjustments, which are necessary for a fair presentation of the results for the interim periods presented, have been included. All such adjustments are of a normal recurring nature. All significant intercompany balances and transactions have been eliminated in consolidation.

The results and trends in these interim financial statements are not necessarily representative of those for the full year, as revenues, expenses, assets and liabilities can vary during each quarter of the year. The information included in this Quarterly Report on Form 10-Q should only be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended September 30, 2005.

Certain amounts in the prior year condensed consolidated financial statements have been reclassified to conform to the current year presentation.

2. INVENTORIES

Inventories at March 31, 2006 and September 30, 2005 are presented below.

	March 31, 2006		September 30, 2005
Raw materials and supplies	$	23,248	$	22,912
Work in process		24,202		23,412
Finished goods		48,911		46,516
	$	96,361	$	92,840

3. GOODWILL AND INTANGIBLE ASSETS

During the first quarter of fiscal 2006, we reviewed the purchase price allocation for the acquisitions of certain assets from Surgical Acuity, Inc. (“Surgical Acuity”) in fiscal 2002 and the stock of SpofaDental a.s. (“SpofaDental”) in fiscal 2003. We determined that a portion of the amount that was allocated to goodwill in fact related to intangible assets, some of which require amortization. Further, upon reviewing the estimated useful life for some of the intangible assets associated with the Innova LifeSciences Corporation (“Innova”) acquisition in fiscal 2005, we determined that the estimated useful life should be reduced. As a result of these determinations, we recorded in the quarter ended December 31, 2005 a non-cash charge of $2,125 to amortization of intangible assets, $1,898 of which related to prior periods. We also identified other errors in the accounting for differences between the assigned values and tax bases of the assets and liabilities recognized in the acquisitions of Innova and Oraltronics Dental Implant Technology GmbH (“Oraltronics”) in fiscal 2005 and SpofaDental in fiscal 2003, which required adjustments to increase goodwill and deferred tax liabilities. All of the above errors occurred over multiple quarters. We concluded that the effect of the errors, individually and in the aggregate, was not material to any of the prior periods in which they occurred and that the correcting entries were not material to the first quarter of fiscal 2006.

5

Goodwill

We perform an annual impairment test of goodwill in the first quarter of each fiscal year, or more frequently if indicators of potential impairment exist, to determine if the recorded goodwill is impaired. To perform this assessment, we identify our reporting units and determine the carrying value of each reporting unit by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units. We then determine the fair value of each reporting unit and compare it to the carrying amount of the reporting unit. We determined that none of our goodwill was impaired as of December 31, 2005. We were not aware of any indicators of potential impairment as of March 31, 2006 or September 30, 2005.

The following table details the balances of the goodwill assets by business segment as of the dates indicated:

	March 31, 2006		September 30, 2005
Professional Dental	$	176,210	$	187,772
Specialty Products		113,859		107,534
Total	$	290,069	$	295,306

The decrease of $5,237 in the amount of goodwill during the six months ended March 31, 2006 was due to an adjustment of $2,779 to the Oraltronics purchase price allocation; an adjustment of $1,069 to the Innova purchase price allocation; $563 of net corrections related to the aforementioned prior period accounting errors; an unfavorable foreign currency fluctuation of $253; and other of $573. We finalized the allocation of the Oraltronics and Innova purchase prices during the six months ended March 31, 2006. The $563 of net corrections mentioned above consists of the following: we reclassified $11,210 from goodwill to intangible assets to account for certain intangible assets that should have been recognized apart from goodwill in prior period business combinations; and we increased goodwill by $10,647 and recognized a deferred tax liability in the same amount to account for differences between the assigned values and tax bases of the assets and liabilities recognized in prior period business combinations.

Intangible Assets

Finite lived intangible assets are recorded at cost and are amortized over their estimated useful lives using the straight-line method. Indefinite lived intangible assets are not amortized but rather are tested for impairment annually. The following table details the balances of our intangible assets as of March 31, 2006:

	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangible Assets Subject to Amortization:
Proprietary technology	$	32,394	$	3,269	$	29,125
Patents		9,157		3,801		5,356
Non-compete agreements		1,673		1,300		373
License agreements		1,875		1,846		29
Customer relationships		7,687		1,739		5,948
Total	$	52,786	$	11,955		40,831
Intangible Assets Not Subject to Amortization:
Trademarks						22,863
Total Intangible Assets					$	63,694

6

The following table details the balances of our intangible assets as of September 30, 2005:

	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangible Assets Subject to Amortization:
Proprietary technology	$	28,827	$	1,166	$	27,661
Patents		8,820		3,418		5,402
Non-compete agreements		1,673		1,273		400
License agreements		1,932		1,886		46
Customer relationships		2,142		177		1,965
Total	$	43,394	$	7,920		35,474
Intangible Assets Not Subject to Amortization:
Trademarks						15,408
Total Intangible Assets					$	50,882

The gross carrying amount of intangible assets subject to amortization increased by $9,392 during the six months ended March 31, 2006. The increase was due to the reclassification of $6,310 from goodwill to intangible assets subject to amortization as a result of the correction of prior period accounting errors, the reclassification of $2,594 from goodwill to intangible assets subject to amortization as a result of the finalization of the Oraltronics purchase price allocation, added patents of $358, foreign currency fluctuation of $159, and other of $574, partially offset by the reclassification of $603 from proprietary technology to trademarks.

The gross carrying amount of our trademarks, which are not subject to amortization, increased by $7,455 during the six months ended March 31, 2006. The increase was due to the reclassification of $4,900 from goodwill to trademarks as a result of the correction of prior period accounting errors, the reclassification of $900 from goodwill to intangible assets subject to amortization as a result of the finalization of the Innova purchase price allocation, the reclassification of $603 from proprietary technology to trademarks, the reclassification of $560 from goodwill to intangible assets subject to amortization as a result of the finalization of the Oraltronics purchase price allocation, foreign currency fluctuation of $111, and other of $381.

Amortization expense for the three months and six months ended March 31, 2006 was $1,299 and $4,113, respectively, as compared to $559 and $1,056 for the three months and six months ended March 31, 2005, respectively. The increase in amortization expense from 2005 to 2006 was due to the correction of prior period accounting errors, as discussed above. Amortization of intangible assets is included as a component of total selling, general and administrative expenses. The following table displays the estimated amortization (calculated as of March 31, 2006) for each of the fiscal years indicated:

	Fiscal year ended September 30,
	2006		2007		2008		2009		2010
Amortization of intangible assets	$	5,756	$	3,257	$	3,228	$	3,187	$	3,148

4. EMPLOYEE BENEFIT PLANS

Pension and Other Postretirement Benefits: We sponsor various defined benefit pension plans covering substantially all of our U.S. and Canadian employees. The benefits are generally based on various formulas, the principal factors of which are years of service and compensation. Plan assets are invested primarily in U.S. stocks, bonds and international stocks. In addition to the defined benefit pension plans, we provide certain health care benefits for certain U.S. employees, which are funded as costs are incurred. Certain salaried employees who reached age 55 prior to January 1, 1996 became eligible for postretirement health care benefits, if they reached retirement age while working for SDS. Our contributions to the cost of the postretirement health care plans for these employees are frozen at a fixed amount for each participant, except where early retirement agreements prohibit such a freeze. In addition, under the current collective bargaining agreement between Kerr Corporation and the United Auto Workers, the bargaining unit employees qualify for postretirement health care benefits. We accrue, as current costs, the future lifetime retirement benefits for all qualifying active and retired employees.

7

The following table provides the components of net periodic benefit cost:

	Pension Benefits												Other Postretirement Benefits
	Three Months Ended March 31,						Six Months Ended March 31,						Three Months Ended March 31,					Six Months Ended March 31,
	2006			2005			2006			2005			2006			2005		2006			2005
Service cost	$	1,516		$	1,094		$	3,033		$	2,188		$	145		$	149	$	290		$	298
Interest cost		1,136			972			2,271			1,944			233			253		467			506
Expected return on plan assets		(1,416	)		(1,108	)		(2,832	)		(2,216	)		—			—		—			—
Amortization of prior service cost		28			24			56			48			(86	)		—		(172	)		—
Amortization of actuarial loss		475			241			950			482			240			153		479			306
Net periodic benefit cost	$	1,739		$	1,223		$	3,478		$	2,446		$	532		$	555	$	1,064		$	1,110

Our funding policy is to generally make annual contributions in excess of both the minimum contributions required by applicable regulations and the amount needed in order to avoid any Pension Benefit Guarantee Corporation (“PBGC”) variable premium payments, and to not have any additional minimum liability under SFAS No. 87, Employers’ Accounting for Pensions. We expect to contribute approximately $1,098 to our pension plan assets in fiscal 2006. We made approximately $213 in contributions in the quarter ended March 31, 2006.

5. RESTRUCTURING CHARGES

In fiscal 2005, we implemented and completed a plan to consolidate our Demetron and Orascoptic operations into one facility. As a result of this plan, we recorded a restructuring charge of $1,204 ($819 after tax) in the fiscal year ended September 30, 2005. The $1,204 restructuring charge was comprised of approximately $616 of cash charges related to severance and termination costs associated with the employees whose employment we terminated as a result of the consolidation; approximately $314 of cash charges related to lease termination, storage and moving costs; and approximately $274 of cash charges related to miscellaneous consolidation costs. Approximately $588 of the costs was recorded as a component of costs of goods sold, and $616 of the costs was recorded as selling, general and administrative expenses. A balance of $56 remains in our accrued liabilities, which is expected to be paid by the end of fiscal 2006.

In fiscal 2004, we implemented and completed a plan to close our facility in Tijuana, Mexico by the end of the first quarter of fiscal 2005. As a result of this plan, we recorded a restructuring charge of $1,471 ($986 after tax) in the fiscal year ended September 30, 2004. The charge was comprised of severance and termination costs associated with the 246 employees whose employment we terminated as a result of the closure and recorded as a component of cost of goods sold in the fiscal year. The 2004 restructuring was completed in the first quarter of fiscal 2005, and all severance was paid.

In September 2002, we recorded a restructuring charge of approximately $3,666 ($2,353 after tax). The charge was primarily comprised of severance and termination costs associated with the 71 employees whose employment we terminated as a result of the consolidation of several of our European facilities into our Hawe Neos facility in Switzerland. Of the $3,666 restructuring charge, approximately $3,064 was related to cash payments for severance and contractual obligations; $300 was for the cash payment of tax liabilities included in income taxes payable; and the balance of approximately $302 related to non-cash charges. We completed the 2002 restructuring in fiscal 2004 and made an adjustment to restructuring charges of approximately $200, primarily for over accruals for anticipated costs associated with severance and related costs. A balance of $300 will remain in our accrued tax liability until it is remitted.

6. SEGMENT INFORMATION

We are a leading manufacturer of both a broad range of value-added products for the dental profession, including the specialty markets of orthodontics, endodontics and implantology, and a variety of infection prevention products for use by the dental and medical professions. Our subsidiaries operate in two business segments: Professional Dental and Specialty Products.

Our corporate office general and administrative expenses have been allocated to the segments on the basis of their net sales.

8

The following tables present the results of operations for our business segments for the three month and six month periods ended March 31, 2006 and 2005:

Three Months Ended March 31,	Professional Dental		Specialty Products		Eliminations			Total
2006
Revenues:
External customer	$	97,060	$	85,726	$	—		$	182,786
Intersegment		520		848		(1,368	)		—
Total revenues	$	97,580	$	86,574	$	(1,368	)	$	182,786
Gross profit	$	54,075	$	50,570	$	—		$	104,645
Selling, general and administrative expenses		34,208		35,958		—			70,166
Operating income	$	19,867	$	14,612	$	—		$	34,479
2005
Revenues:
External customer	$	87,567	$	77,489	$	—		$	165,056
Intersegment		476		923		(1,399	)		—
Total revenues	$	88,043	$	78,412	$	(1,399	)	$	165,056
Gross profit	$	49,465	$	43,720	$	—		$	93,185
Selling, general and administrative expenses		30,686		29,568		—			60,254
Operating income	$	18,779	$	14,152	$	—		$	32,931
Six Months Ended March 31,	Professional Dental		Specialty Products		Eliminations			Total
2006
Revenues:
External customer	$	176,244	$	164,573	$	—		$	340,817
Intersegment		1,298		1,503		(2,801	)		—
Total revenues	$	177,542	$	166,076	$	(2,801	)	$	340,817
Gross profit	$	97,238	$	97,397	$	—		$	194,635
Selling, general and administrative expenses		65,574		68,676		—			134,250
Operating income	$	31,664	$	28,721	$	—		$	60,385
2005
Revenues:
External customer	$	163,454	$	150,642	$	—		$	314,096
Intersegment		1,321		1,754		(3,075	)		—
Total revenues	$	164,775	$	152,396	$	(3,075	)	$	314,096
Gross profit	$	91,023	$	87,529	$	—		$	178,552
Selling, general and administrative expenses		60,672		57,567		—			118,239
Operating income	$	30,351	$	29,962	$	—		$	60,313

The following table presents the segment assets as of March 31, 2006 compared to the prior fiscal year end:

	Professional Dental		Specialty Products		Total
March 31, 2006	$	517,272	$	268,620	$	785,892
September 30, 2005	$	489,278	$	261,140	$	750,418

9

7. EARNINGS PER SHARE

Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing net income by the combination of dilutive common share equivalents, comprised of shares issuable under our stock-based compensation plans, and the weighted average number of common shares outstanding during the reporting period. The table below reflects the potential dilutive effect on shares outstanding, which is calculated using the treasury stock method, of additional common shares that are issuable upon exercise of outstanding stock options.

	Three Months Ended March 31,		Six Months Ended March 31,
	2006	2005	2006	2005
Basic shares outstanding (weighted average)	40,518	39,986	40,463	39,732
Effect of dilutive securities	1,511	1,499	1,566	1,544
Diluted shares outstanding	42,029	41,485	42,029	41,276

During the three month and six month periods ended March 31, 2006, weighted average options outstanding to purchase approximately 3,265 shares and 3,257 shares, respectively, of common stock were not included in the computation of dilutive securities because inclusion would be anti-dilutive, as compared to approximately 100 shares and 60 shares for the three month and six month periods ended March 31, 2005, respectively.

8. STOCK-BASED COMPENSATION

Effective October 1, 2005, we adopted Statement of Financial Accounting Standards No. 123 (revised 2004), Share Based Payment (“SFAS No. 123R”). SFAS No. 123R establishes the financial accounting and reporting standards for stock-based compensation plans. As required by SFAS No. 123R, we recognized the cost resulting from all stock-based payment transactions including shares issued under our stock option plans and Employee Stock Purchase Plan (“ESPP”) in the financial statements. As a result of adopting SFAS No. 123R, our net income for the three month and six month periods ended March 31, 2006 was $2,461 and $4,197 lower, respectively and net of taxes, than if we had continued to account for stock-based compensation under Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and its related interpretations (“APB Opinion No. 25”). At March 31, 2006, there was $48,293 of total unrecognized compensation costs related to unvested stock-based compensation arrangements granted under the stock option plans and ESPP. That cost is expected to be amortized on a straight-line basis over a weighted average period of 4.1 years less any stock options forfeited prior to vesting. During the three month and six month periods ended March 31, 2006, $99 and $202, respectively, of stock-based compensation cost was capitalized as inventory and expensed through cost of goods sold. No stock-based compensation cost was capitalized as inventory and expensed through cost of goods sold during the three month and six month periods ended March 31, 2005.

Prior to October 1, 2005, we accounted for stock-based employee compensation plans (including shares issued under our stock option plans and ESPP) in accordance with APB Opinion No. 25 and followed the pro forma net income, pro forma income per share, and stock-based compensation plan disclosure requirements set forth in the Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation (“SFAS No. 123”).

10

The following table sets forth the computation of basic and diluted income per share for the three month and six month periods ended March 31, 2005 and illustrates the effect on net income and earnings per share as if we had applied the fair value recognition provisions of SFAS No. 123 to stock-based employee compensation (dollars in thousands, except per share amounts):

	Three Months Ended March 31, 2005			Six Months Ended March 31, 2005
Net income, as reported	$	19,438		$	34,477
Add: Stock-based employee compensation expense included in reported net income, net of related tax effects		—			—
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects		(589	)		(1,502	)
Pro forma net income	$	18,849		$	32,975
Earnings per share:
Basic – as reported	$	0.49		$	0.87
pro forma	$	0.47		$	0.83
Diluted – as reported	$	0.47		$	0.84
pro forma	$	0.45		$	0.80

Fair Value Disclosures

Prior to April 1, 2005, we used the Black-Scholes option-pricing model to estimate a valuation for stock options. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no restrictions and are fully transferable and negotiable in a free trading market. This model does not consider the employment, transfer or vesting restrictions that are inherent in our employee stock options or purchase rights granted pursuant to the ESPP. During fiscal 2005, we conducted an evaluation of the benefits of using a binomial-lattice model rather than the Black-Scholes model. A binomial-lattice model considers historical patterns of employee exercise behavior and stock price volatility to project an appropriate array of future exercise behaviors. As a result of the evaluation, we concluded that a binomial-lattice model provides a more accurate estimated valuation for stock options and have adopted a binomial-lattice model to estimate the fair value of stock options granted subsequent to March 31, 2005.

The weighted average expected volatility for stock options granted prior to March 31, 2005 was based on historical experience of employees’ stock option exercise behavior. The weighted average expected volatility for stock options granted subsequent to March 31, 2005 was based on several components in accordance with our modified prospective adoption of SFAS No. 123R, on October 1, 2005. Components to the weighted average expected volatility for stock options granted subsequent to March 31, 2005 include historical volatility of the stock price, expected life of the option, and length of time shares have been publicly traded. Implied volatility of actively traded option contracts on our common stock was excluded from the calculation. As options of our stock are not actively traded on the open market, sufficient data for an accurate measure of implied volatility was not available.

During the periods that the Black-Scholes stock option pricing model was used to value our stock option grants, the risk free interest rate reflected the yield on zero coupon U.S. treasuries at the date of grant, based on the median time the options granted are expected to be outstanding. During the period that the binomial-lattice model was used to value our stock option grants, the risk-free interest rate was determined using the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option.

Expected dividend yield is based on historical dividend payments and expected future dividend payments.

We use historical data to estimate option exercise and employee termination within the valuation model; separate groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The expected life for each award granted is derived from the output of the valuation model and represents the median time that options granted are expected to be outstanding.

11

Stock Options

Our employee stock option plans are part of a broad-based, long term retention program to promote success, and to enhance the value of the Company by linking personal interests of the participants to those of our stockholders, and by providing participants with an incentive for outstanding performance.

We currently have four long-term incentive plans including the 2000 Long-Term Incentive Plan (the “2000 Stock Plan”), the 2001 Long-Term Incentive Plan (the “2001 Stock Plan”), the 2005 Long-Term Incentive Plan (the “2005 Stock Plan”), and the 2006 Restricted Stock Incentive Plan (the “2006 Stock Plan”). The 2006 Stock Plan was approved at the 2006 Annual Meeting of Stockholders. Under the 2006 Stock Plan restricted stock awards may be granted to employees, including employees who are members of the Board of Directors, but excluding any director who is not an employee. Under the 2000 and 2005 Stock Plans, stock options may be granted to employees, including employees who are members of the Board of Directors, but excluding any director who is not an employee. Under the 2001 Stock Plan, stock options may be granted to employees, other than employees who are officers (as that term is defined in Rule 16a-1(f) under the Exchange Act) or directors. Subject to the terms and provisions of the plans, options may be granted to eligible employees selected by the Compensation Committee of the Board of Directors, which administers the plans. The Compensation Committee has the discretion to determine the number of shares subject to options granted and the terms and conditions of the option grants. The exercise price of an option granted under the plans is determined by the Compensation Committee, but may not be less than 100% of the fair market value of our underlying common stock on the date of grant.

The total number of shares of our common stock authorized for issuance under the 2000, 2001, 2005, and 2006 Stock Plans is 5,450, 1,000, 4,000, and 100, respectively. Shares available for an award under the 2000, 2001, 2005, and 2006 Stock Plans may be either authorized but unissued or reacquired shares. If any award cancels, terminates, expires or lapses for any reason, any shares subject to such award shall again be available under the appropriate Stock Plan, subject to such requirements as may be promulgated by the Compensation Committee.

Restricted stock awards granted under the 2006 Stock Plan shall be subject to a minimum restriction period of two years of continuous service before a restricted stock award shall fully vest. The restricted period shall be determined at the discretion of the Compensation Committee. At the end of the restriction period the restrictions imposed shall lapse with respect to the number of shares of restricted stock as determined by the Compensation Committee and an unlegended certificate for the number of shares shall be delivered to the holder.

Options granted under the 2000, the 2001, and 2005 Stock Plans are exercisable for up to ten years from the date of grant. Stock options vest under the plans subject to the restrictions and conditions that the Compensation Committee approves. Typically the vesting schedule is 25% per year based on the date of grant for the 2000 Stock Plan and the 2001 Stock Plan, and 5 year cliff vesting for the 2005 Stock Plan.

We currently have two Outside Directors’ plans—the 2000 Outside Directors’ Stock Option Plan (the “2000 Directors’ Plan”) and the 2005 Outside Directors’ Stock Plan (the “2005 Directors’ Plan”). The 2005 Directors’ Plan was approved at our 2005 Annual Meeting of Stockholders. A maximum of 300 and 350 shares of our common stock may be issued pursuant to the exercise of stock options granted under the 2000 and 2005 Directors’ Plans, respectively. If any award cancels, terminates, expires or lapses for any reason, any shares subject to such award shall again be available under the appropriate Directors’ Plan, subject to such requirements as may be promulgated by the Compensation Committee. These options are exercisable up to ten years from date of grant and vest on the date of grant.

The granting of options is automatic under the 2000 and 2005 Directors’ Plans. Upon the first meeting of the Board of Directors following the Annual Meeting of Stockholders in 2001 through 2005 under the 2000 Directors’ Plan and 2006 through 2010 under the 2005 Directors’ Plan, each person then serving as a member of the Board of Directors who is not one of our full-time employees shall automatically be granted an option to purchase 10 shares of our common stock (subject to appropriate adjustment for stock splits and other changes affecting the common stock). If there is not a sufficient number of remaining available shares under the 2000 or 2005 Directors’ Plans to grant each outside director an option to purchase the number of shares specified, each outside director shall receive an option to purchase an equal number of the remaining available shares, determined by dividing the remaining available shares by the number of outside directors. The exercise price at which shares may be purchased under each option shall be 100% of the fair market value of our common stock on the date the option is granted.

At March 31, 2006, 1,372 shares of common stock were reserved for future stock option grants under the above plans.

12

During the three and six months ended March 31, 2006, we granted 270 stock options. During the three and six months ended March 31, 2005, we granted 100 stock options. Stock options issued under the stock option plans during the three month and six month periods ended March 31, 2006 and 2005 were based on the following weighted average assumptions:

	Stock Options
	Three Months Ended March 31,						Six Months Ended March 31,
	2006			2005			2006			2005
Expected life (years)		7.67			4.00			7.67			4.00
Weighted-average volatility		27.58	%		28.62	%		27.58	%		28.62	%
Risk free interest rate		4.60	%		3.54	%		4.60	%		3.54	%
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%
Weighted average fair value of options granted	$	16.37		$	11.35		$	16.37		$	11.35

Shares issued under the ESPP during the three month and six month periods ended March 31, 2006 and 2005 were based on the following weighted average assumptions:

	Employee Stock Purchase Plan
	Six Months Ended March 31,
	2006			2005
Expected life (years)		0.5			0.5
Weighted-average volatility		24.84	%		19.57	%
Risk free interest rate		3.19	%		2.52	%
Expected dividend yield		0.00	%		0.00	%
Weighted average fair value of options granted	$	8.46		$	9.58

The following is a summary of the stock option activity for the six month period ended March 31, 2006:

	Number of Options		Weighted Average Exercise Price			Remaining Contractual Term	Aggregate Intrinsic Value
Options outstanding at September 30, 2005	6,976		$	26.50
Granted	—			—
Exercised	(59	)		(17.59	)
Canceled	(42	)		(34.50	)
Options outstanding at December 31, 2005	6,875		$	26.52		7.04	$	91,345
Granted	270			39.42
Exercised	(69	)		(14.85	)
Canceled	(2	)		(11.29	)
Options outstanding at March 31, 2006	7,074		$	27.13		6.95	$	99,784
Options exercisable at March 31, 2006	3,351		$	16.60		4.66	$	82,594

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an exercise price currently below the quoted price. During the three month and six month periods ended March 31, 2006, the aggregate intrinsic value (determined as of the date of exercise) of options exercised under the stock option plans was $1,705 and $3,029, respectively, as compared to $2,779 and $14,004 for the three month and six month periods ended March 31, 2005, respectively.

Cash received from option exercises under all stock-based payment arrangements for the three month and six month periods ended March 31, 2006 was $952 and $1,984, respectively, as compared to $2,386 and $10,254 for the three month and six month periods ended March 31, 2005, respectively. The actual tax benefit realized from the tax deductions for options exercised totaled $468 and $887, respectively, for the three month and six month periods ended March 31, 2006, as compared to $685 and $4,736 for the three month and six month periods ended March 31, 2005, respectively. For purposes of satisfying stock option exercises, we have a policy of issuing new shares to fulfill exercises.

13

Employee Stock Purchase Plan

The ESPP was approved by stockholders at the 2003 Annual Meeting of Stockholders. Under the terms of the ESPP, 500 shares of common stock were reserved for issuance to our employees, nearly all of whom are eligible to participate. As of March 31, 2006, 350 shares remain available for issuance to our employees. Under the terms of the ESPP, employees can choose each year to have one to ten percent of their base pay withheld, not to exceed amounts allowed by the Internal Revenue Code, to purchase our common stock. The purchase price of the stock is 85 percent of the lower of its price at the beginning or end of each six month offering period. During the three month and six month periods ended March 31, 2006, 36 shares of common stock were purchased at an average price of $31.91 per share, as compared to 30 shares purchased at an average price of $25.32 during the three month and six month periods ended March 31, 2005.

9. DERIVATIVES

During the three month period ended December 31, 2005, we settled all of the five outstanding cross currency debt swap contracts used to hedge our foreign currency exposure because these instruments were getting close to maturity. The settlement of the cross currency debt swaps generated interest income of approximately $411 and a cumulative loss of $8,948 ($5,548 net of income tax) in the currency translation adjustment account in equity during the three month period ended December 31, 2005. At March 31, 2006, a total of $10,527 realized loss ($6,511 net of income tax), including the realized loss of $1,579 ($963 net of income tax) as a result of cash-settling a cross currency swap with Wachovia in 2002, was included in the currency translation adjustment account in equity. This realized loss will remain in the currency translation adjustment account in equity until we dispose of the net investments.

10. CONDENSED CONSOLIDATING FINANCIAL INFORMATION

Our domestic subsidiaries are guarantors of our 8 1/8% Senior Subordinated Notes due 2012, on an unsecured senior subordinated basis. Except to the extent necessary to avoid a fraudulent conveyance, the note guarantees are full and unconditional. The notes and the subsidiary guarantees are unsecured and subordinated to our and to all of our guarantor subsidiaries’ existing and future unsubordinated debt, including debt under the Credit Facility entered into on June 6, 2002.

Below are the unaudited condensed consolidating balance sheets as of March 31, 2006 and September 30, 2005, statements of operations for the three month and six month periods ended March 31, 2006 and 2005, and statements of cash flows for the six months ended March 31, 2006 and 2005, of Sybron Dental Specialties, Inc. and its subsidiaries, reflecting the subsidiary guarantors of the Senior Subordinated Notes.

Certain general corporate expenses have been allocated to the subsidiaries. As a matter of course, we retain certain assets and liabilities at the corporate level that are not allocated to the subsidiaries including, but not limited to, certain employee benefit, insurance and tax liabilities. Intercompany balances include receivables/payables incurred in the normal course of business in addition to investments and loans transacted by subsidiaries with other subsidiaries or with us.

14

Condensed Consolidating Balance Sheets

	As of March 31, 2006
	Sybron Dental Specialties			Guarantor Subsidiaries			Non Guarantor Subsidiaries		Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	(1,028	)	$	(4,724	)	$	81,548	$	—		$	75,796
Accounts receivable, net		(8	)		62,568			54,260		—			116,820
Inventories		—			62,879			33,613		(131	)		96,361
Other current assets		13,268			11,032			2,414		—			26,714
Total current assets		12,232			131,755			171,835		(131	)		315,691
Property, plant and equipment, net		9,892			32,250			44,403		—			86,545
Goodwill		—			193,046			97,023		—			290,069
Intangible assets, net		—			19,174			44,520		—			63,694
Investment in subsidiaries		948,343			—			—		(948,343	)		—
Intercompany balances		—			185,872			123,025		(308,897	)		—
Other assets		23,344			3,440			3,109		—			29,893
Total assets	$	993,811		$	565,537		$	483,915	$	(1,257,371	)	$	785,892
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	622		$	12,043		$	6,832	$	—		$	19,497
Current portion of long-term debt		—			143			—		—			143
Income taxes payable		(4,356	)		7,863			11,622		92			15,221
Accrued expenses and other current liabilities		15,755			21,460			21,468		—			58,683
Total current liabilities		12,021			41,509			39,922		92			93,544
Long-term debt		45,500			7,452			—		—			52,952
Senior subordinated notes		150,000			—			—		—			150,000
Deferred income taxes		16,439			—			5,984		—			22,423
Other liabilities		14,566			382			5,860		—			20,808
Intercompany balances		309,120			—			—		(309,120	)		—
Total liabilities		547,646			49,343			51,766		(309,028	)		339,727
Stockholders’ equity:
Preferred stock		—			—			—		—			—
Common stock		406			3,080			16,678		(19,758	)		406
Additional paid-in capital		128,730			307,935			256,281		(564,216	)		128,730
Retained earnings		298,055			188,794			140,954		(329,748	)		298,055
Accumulated other comprehensive income		18,974			16,385			18,236		(34,621	)		18,974
Total stockholders’ equity		446,165			516,194			432,149		(948,343	)		446,165
Total liabilities and stockholders’ equity	$	993,811		$	565,537		$	483,915	$	(1,257,371	)	$	785,892

15

Condensed Consolidating Balance Sheets

	As of September 30, 2005
	Sybron Dental Specialties			Guarantor Subsidiaries			Non Guarantor Subsidiaries			Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	(1,494	)	$	(2,154	)	$	62,220		$	—		$	58,572
Accounts receivable, net		(1	)		59,412			53,089			—			112,500
Inventories		—			60,396			32,444			—			92,840
Other current assets		11,550			3,164			5,335			—			20,049
Total current assets		10,055			120,818			153,088			—			283,961
Property, plant and equipment, net		8,922			32,304			46,536			—			87,762
Goodwill		—			197,756			97,550			—			295,306
Intangible assets, net		—			15,553			35,329			—			50,882
Investment in subsidiaries		917,199			—			—			(917,199	)		—
Intercompany balances		—			213,578			123,540			(337,118	)		—
Other assets		21,857			7,930			2,720			—			32,507
Total assets	$	958,033		$	587,939		$	458,763		$	(1,254,317	)	$	750,418
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	659		$	11,040		$	8,436		$	—		$	20,135
Current portion of long-term debt		51			682			—			—			733
Income taxes payable		8,727			(4,744	)		7,839			—			11,822
Accrued expenses and other current liabilities		13,437			25,445			20,922			—			59,804
Total current liabilities		22,874			32,423			37,197			—			92,494
Long-term debt		7,200			53,899			—			—			61,099
Senior subordinated notes		150,000			—			—			—			150,000
Deferred income taxes		16,601			—			(196	)		—			16,405
Other liabilities		22,087			345			5,835			—			28,267
Intercompany balances		337,118			—			—			(337,118	)		—
Total liabilities		555,880			86,667			42,836			(337,118	)		348,265
Stockholders’ equity:
Preferred stock		—			—			—			—			—
Common stock		404			3,446			16,312			(19,758	)		404
Additional paid-in capital		118,448			311,378			252,837			(564,215	)		118,448
Retained earnings		264,841			170,656			127,855			(298,511	)		264,841
Accumulated other comprehensive income		18,460			15,792			18,923			(34,715	)		18,460
Total stockholders’ equity		402,153			501,272			415,927			(917,199	)		402,153
Total liabilities and stockholders’ equity	$	958,033		$	587,939		$	458,763		$	(1,254,317	)	$	750,418

16

Condensed Consolidating Statements of Income

	For The Three Months Ended March 31, 2006
	Sybron Dental Specialties			Guarantor Subsidiaries			Non Guarantor Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	98,333		$	85,822		$	(1,369	)	$	182,786
Cost of sales		319			30,101			48,959			(1,238	)		78,141
Gross profit		(319	)		68,232			36,863			(131	)		104,645
Selling, general and administrative expenses		13,665			34,303			22,198			—			70,166
Operating income (loss)		(13,984	)		33,929			14,665			(131	)		34,479
Other income (expense):
Interest expense, net		(3,358	)		(908	)		160			—			(4,106	)
Amortization of deferred financing fees		—			(2,346	)		—			—			(2,346	)
Income from subsidiaries		19,966			—			—			(19,966	)		—
Other, net		15,377			(13,231	)		(1,920	)		—			226
Income before income taxes		18,001			17,444			12,905			(20,097	)		28,253
Income taxes		(473	)		5,146			4,619			275			9,567
Net income	$	18,474		$	12,298		$	8,286		$	(20,372	)	$	18,686
	For The Three Months Ended March 31, 2005
	Sybron Dental Specialties			Guarantor Subsidiaries			Non Guarantor Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	89,169		$	77,286		$	(1,399	)	$	165,056
Cost of sales		301			31,216			41,753			(1,399	)		71,871
Gross profit		(301	)		57,953			35,533			—			93,185
Selling, general and administrative expenses		9,012			31,497			19,745			—			60,254
Operating income (loss)		(9,313	)		26,456			15,788			—			32,931
Other income (expense):
Interest expense, net		(3,497	)		(1,113	)		190			—			(4,420	)
Amortization of deferred financing fees		—			(416	)		—			—			(416	)
Income from subsidiaries		19,438			—			—			(19,438	)		—
Other, net		12,810			(10,544	)		(1,776	)		—			490
Income before income taxes		19,438			14,383			14,202			(19,438	)		28,585
Income taxes		—			6,238			2,909			—			9,147
Net income	$	19,438		$	8,145		$	11,293		$	(19,438	)	$	19,438

17

Condensed Consolidating Statements of Income

	For The Six Months Ended March 31, 2006
	Sybron Dental Specialties			Guarantor Subsidiaries			Non Guarantor Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	183,815		$	159,804		$	(2,802	)	$	340,817
Cost of sales		597			57,767			90,489			(2,671	)		146,182
Gross profit		(597	)		126,048			69,315			(131	)		194,635
Selling, general and administrative expenses		21,443			66,570			46,237			—			134,250
Operating income (loss)		(22,040	)		59,478			23,078			(131	)		60,385
Other income (expense):
Interest expense, net		(6,649	)		(1,554	)		240			—			(7,963	)
Amortization of deferred financing fees		—			(2,759	)		—			—			(2,759	)
Income from subsidiaries		34,493			—			—			(34,493	)		—
Other, net		26,725			(22,604	)		(3,848	)		—			273
Income before income taxes		32,529			32,561			19,470			(34,624	)		49,936
Income taxes		(473	)		11,981			5,122			92			16,722
Net income	$	33,002		$	20,580		$	14,348		$	(34,716	)	$	33,214
	For The Six Months Ended March 31, 2005
	Sybron Dental Specialties			Guarantor Subsidiaries			Non Guarantor Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	167,459		$	149,712		$	(3,075	)	$	314,096
Cost of sales		594			56,592			81,433			(3,075	)		135,544
Gross profit		(594	)		110,867			68,279			—			178,552
Selling, general and administrative expenses		15,745			61,528			40,966			—			118,239
Operating income (loss)		(16,339	)		49,339			27,313			—			60,313
Other income (expense):
Interest expense, net		(7,095	)		(2,462	)		320			—			(9,237	)
Amortization of deferred financing fees		—			(831	)		—			—			(831	)
Income from subsidiaries		34,477			—			—			(34,477	)		—
Other, net		23,434			(19,466	)		(3,512	)		—			456
Income before income taxes		34,477			26,580			24,121			(34,477	)		50,701
Income taxes		—			11,019			5,205			—			16,224
Net income	$	34,477		$	15,561		$	18,916		$	(34,477	)	$	34,477

18

Condensed Consolidating Statements of Cash Flows

	For The Six Months Ended March 31, 2006
	Sybron Dental Specialties			Guarantor Subsidiaries			Non Guarantor Subsidiaries			Eliminations		Consolidated
Cash flows provided by/(used in) operating activities	$	(778	)	$	21,659		$	28,712		$	—	$	49,593
Cash flows from investing activities:
Capital expenditures		(2,714	)		(3,968	)		(1,647	)		—		(8,329	)
Proceeds from sales of property, plant and equipment		—			—			7			—		7
Acquisition escrow deposit		—			—			(7,907	)		—		(7,907	)
Payments for intangibles		—			(358	)		(28	)		—		(386	)
Net cash used in investing activities		(2,714	)		(4,326	)		(9,575	)		—		(16,615	)
Cash flows from financing activities:
Proceeds from credit facility		137,100			—			—			—		137,100
Principal payments on credit facility		(98,801	)		(46,909	)		—			—		(145,710	)
Settlement of derivative instruments		(8,384	)		—			—			—		(8,384	)
Principal payments on long-term debt		(21	)		(106	)		—			—		(127	)
Payment of deferred financing fees		(1,164	)		—			—			—		(1,164	)
Proceeds from exercise of stock options		1,984			—			—			—		1,984
Proceeds from employee stock purchase plan		1,149			—			—			—		1,149
Net cash provided by/(used in) financing activities		31,863			(47,015	)		—			—		(15,152	)
Effect of exchange rate changes on cash and cash equivalents		317			(229	)		(690	)		—		(602	)
Net change in intercompany balances		(28,222	)		27,341			881			—		—
Net increase/(decrease) in cash and cash equivalents		466			(2,570	)		19,328			—		17,224
Cash and cash equivalents at beginning of period		(1,494	)		(2,154	)		62,220			—		58,572
Cash and cash equivalents at end of period	$	(1,028	)	$	(4,724	)	$	81,548		$	—	$	75,796
Supplemental cash flow information:
Cash paid during the period for interest	$	6,650		$	2,082		$	—		$	—	$	8,732
Cash paid during the period for income taxes	$	7,476		$	—		$	4,764		$	—	$	12,240
	For The Six Months Ended March 31, 2005
	Sybron Dental Specialties			Guarantor Subsidiaries			Non Guarantor Subsidiaries			Eliminations		Consolidated
Cash flows provided by/(used in) operating activities	$	(50,204	)	$	52,065		$	34,566		$	—	$	36,427
Cash flows from investing activities:
Capital expenditures		(1,609	)		(3,416	)		(1,317	)		—		(6,342	)
Proceeds from sales of property, plant and equipment		—			373			565			—		938
Net payments for businesses acquired		—			—			(46,049	)		—		(46,049	)
Payments for intangibles		—			(849	)		—			—		(849	)
Net cash used in investing activities		(1,609	)		(3,892	)		(46,801	)		—		(52,302	)
Cash flows from financing activities:
Proceeds from credit facility		86,000			—			—			—		86,000
Principal payments on credit facility		(70,300	)		(5,307	)		—			—		(75,607	)
Principal payments on long-term debt		(40	)		(252	)		—			—		(292	)
Proceeds from exercise of stock options		10,254			—			—			—		10,254
Proceeds from employee stock purchase plan		771			—			—			—		771
Net cash provided by/(used in) financing activities		26,685			(5,559	)		—			—		21,126
Effect of exchange rate changes on cash and cash equivalents		(1,507	)		3,070			211			—		1,774
Net change in intercompany balances		19,142			(47,276	)		28,134			—		—
Net increase/(decrease) in cash and cash equivalents		(7,493	)		(1,592	)		16,110			—		7,025
Cash and cash equivalents at beginning of period		7,402			(1,801	)		35,001			—		40,602
Cash and cash equivalents at end of period	$	(91	)	$	(3,393	)	$	51,111		$	—	$	47,627
Supplemental cash flow information:
Cash paid during the period for interest	$	7,027		$	2,565		$	—		$	—	$	9,592
Cash paid during the period for income taxes	$	8,274		$	—		$	5,293		$	—	$	13,567

19

11. SUBSEQUENT EVENTS

On April 12, 2006, we announced a definitive agreement to merge with a subsidiary of Danaher Corporation, a leading manufacturer of professional instrumentation, industrial technologies, and tools and components headquartered in Washington, D.C. The transaction is structured as a cash tender offer for $47.00 per share of our stock, for an aggregate price of approximately $2.0 billion, including transaction costs and net of cash acquired, to be followed by a second-step cash-out merger at the offer price. The transaction is expected to close in the quarter ended June 30, 2006, pending customary conditions, including tender of a majority of the outstanding shares into the offer, and the absence of a material adverse change with respect to SDS. There can be no assurance that the transaction will be consummated.

On April 1, 2006, Pinnacle Products, Inc., a subsidiary in our Professional Dental business segment, acquired the infection prevention product line of Dental Disposables International, Inc. (“DDI”) through an all-cash transaction with a purchase price of $7.9 million, which is subject to a final working capital adjustment.

20